Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)

Brain

Volumn 131, Issue 10, 2008, Pages 2734-2741

  Baier, Paul Christian ^a   Weinhold, Sara Lena ^a   Huth, Verena ^a   Gottwald, Birgit ^a   Ferstl, Roman ^a   Hinze Selch, Dunja ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cataplexy; Hypocretin 1; Narcolepsy; Olfactory dysfunction; Orexin A

Indexed keywords

OREXIN A; PHENETHYL ALCOHOL; PLACEBO;

ADULT; ARTICLE; BODY MASS; CATAPLEXY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NARCOLEPSY; OLFACTORY CORTEX; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMELLING DISORDER; SMOKING;

ADULT; AGED; CASE-CONTROL STUDIES; CATAPLEXY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; OLFACTION DISORDERS; SMELL; SYMPATHOMIMETICS;

EID: 54949146168     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn193     Document Type: Article

References (42)

1. Apelbaum AF, Perrut A, Chaput M. Orexin A effects on the olfactory bulb spontaneous activity and odor responsiveness in freely breathing rats. Regul Pept 2005; 129: 49-61.
2. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International classification of sleep disorders, 2nd edn. Sleep Med Rev 2007; 11: 377-88.
3. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL.. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-6.
4. Caillol M, Aioun J, Baly C, Persuy MA, Salesse R. Localization of orexins and their receptors in the rat olfactory system: possible modulation of olfactory perception by a neuropeptide synthetized centrally or locally. Brain Res 2003; 960: 48-61.
5. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
6. Dalal MA, Schuld A, Pollmacher T. Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsycataplexy. J Sleep Res 2002; 11: 273.
7. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 1999; 96: 748-53.
8. Dauvilliers Y, Baumann CR, Carlander B, Bischof M, Blatter T, Lecendreux M, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003; 74: 1667-73.
9. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007; 27: 14239-47.
10. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95: 322-7.
11. Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol 2007; 21: 460-73.
12. Doty R, Kobal G. Current trends in the measurement of olfactory function. In: Doty R, editor. Handbook of olfaction and Gustation. New York: Dekker; 1995. p. 191-225.
13. Doty RL, McKeown DA, Lee WW, Shaman P. A study of the test-retest reliability of ten olfactory tests. Chem Senses 1995; 20: 645-56.
14. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003; 26: 953-9.
15. Ganjavi H, Shapiro CM. Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci 2007; 19: 413-9.
16. Gorojankina T, Grebert D, Salesse R, Tanfin Z, Caillol M. Study of orexins signal transduction pathways in rat olfactory mucosa and in olfactory sensory neurons-derived cell line Odora: multiple orexin signalling pathways. Regul Pept 2007; 141: 73-85.
17. Hallschmid M, Gais S, Meinert S, Born J. NPY attenuates positive cortical DC-potential shift upon food intake in man. Psychoneuroendocrinology 2003; 28: 529-39.
18. Hardy AB, Aioun J, Baly C, Julliard KA, Caillol M, Salesse R, et al. Orexin A modulates mitral cell activity in the rat olfactory bulb: patch-clamp study on slices and immunocytochemical localization of orexin receptors. Endocrinology 2005; 146: 4042-53.
19. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364-72.
20. Hinze-Selch D, Wetter TC, Zhang Y, Lu HC, Albert ED, Mullington J, et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998; 50: 1149-52.
21. Hublin C, Kaprio J, Partinen M, Koskenvuo M, Heikkila K. The Ullanlinna Narcolepsy Scale: validation of a measure of symptoms in the narcoleptic syndrome. J Sleep Res 1994; 3: 52-9.
22. Hummel T, Kobal G, Gudziol H, Mackay-Sim A. Normative data for the 'Sniffin' Sticks' including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007; 264: 237-43.
23. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000; 3: 23-8.
24. Julliard AK, Chaput MA, Apelbaum A, Aime P, Mahfouz M, Duchamp-Viret P. Changes in rat olfactory detection performance induced by orexin and leptin mimicking fasting and satiation. Behav Brain Res 2007; 183: 123-9.
25. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.
26. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004; 101: 4649-54.
27. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-62.
28. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res 1999; 827: 243-60.
29. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007; 8: 373-99.
30. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001; 50: 381-8.
31. Overeem S, Black JL III, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev 2008; 12: 95-107.
32. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
33. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
34. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
35. Scammell TE, Saper CB. Orexins: looking forward to sleep, back at addiction. Nat Med 2007; 13: 126-8.
36. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 2000; 355: 1274-5.
37. Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, Ueta Y. Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neurosci Res 2008; 61: 99-105.
38. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004; 55: 125-48.
39. Stiasny-Kolster K, Clever SC, Moller JC, Oertel WH, Mayer G. Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain 2007; 130: 442-9.
40. Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-37.
41. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
42. Weess H, Sauter C, Geisler P, Bohning W, Wilhelm B, Rotte M, et al. Vigilance, tendency to fall asleep, sustained attention, tiredness, sleepiness: diagnostic tools for the measurement of sleepiness related processes and their criteria of quality. Somnologie 2000; 4: 20-38.